ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

IMPL Impel Pharmaceuticals Inc (PK)

0.04
0.00 (0.00%)
17 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Impel Pharmaceuticals Inc (PK) USOTC:IMPL OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.04 0.04 0.1649 0.00 01:00:00

- Current report filing (8-K)

14/04/2009 7:01pm

Edgar (US Regulatory)


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) April 9, 2009

CONSORTEUM HOLDINGS, INC.
(Exact name of registrant as specified in its charter)

 Nevada 333-140236
 -------- ---------- ------------------
(State or other jurisdiction (Commission File Number) IRS Employer
of incorporation) Identification No.)

131 Court Street, #11, Exeter, New Hampshire 03833
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code 603 778-9910

IMPLEX CORPORATION
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


ITEM 5.03 AMENDMENTS TO ARTICLES OF INCORPORATION OR BYLAWS; CHANGE IN FISCAL YEAR.

On April 9, 2009 the Company merged its wholly-owned Nevada subsidiary, Consorteum Holdings, Inc., with and into itself and in connection with such merger changed its name from Implex Corporation to that of the subsidiary, Consorteum Holdings, Inc. Except for the change in the Company's name, there were no other changes to the Articles of Incorporation.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IMPLEX CORPORATION

 By: /s/ Richard C. Fox, Pres./CEO
 ------------------

Dated: April 14, 2009

1 Year Impel Pharmaceuticals (PK) Chart

1 Year Impel Pharmaceuticals (PK) Chart

1 Month Impel Pharmaceuticals (PK) Chart

1 Month Impel Pharmaceuticals (PK) Chart

Your Recent History

Delayed Upgrade Clock